Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
暂无分享,去创建一个
L. Gordon | I. Flinn | T. Witzig | G. Wiseman | R. Schilder | C. Emmanouilides | A. Molina | M. Darif | K. Vo